Hualan Biological EngineeringInc

Price Chart

Risk-Adjusted Performance

Hualan Biological EngineeringInc (002007) Price Performance

Hualan Biological EngineeringInc (002007) trades on SHE in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY15.04, down 0.20% from the previous close.

Over the past year, 002007 has traded between a low of CNY14.34 and a high of CNY17.19. The stock has lost 4.0% over this period. It is currently 12.5% below its 52-week high.

Hualan Biological EngineeringInc has a market capitalization of $27.48B, with a price-to-earnings ratio of 28.92 and a dividend yield of 6.64%.

About Hualan Biological EngineeringInc

Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally. The company offers blood products, including human serum albumin, human prothrombin complex concentrate, human coagulation factor VIII, human fibrinogen, and freeze-dried human fibrin glue for surgical use, as well as intravenous, human, rabies, hepatitis B, and tetanus immunoglobulin for various therapeutic applications. It also provides vaccine products, such as influenza virus split, H1N1 influenza A virus split, quadrivalent influenza virus split, group A and C meningococcal polysaccharide, group ACYW135 meningococcal polysaccharide, recombinant hepatitis B vaccine, freeze-dried human rabies, and adsorbed tetanus vaccines. In addition, the company develops monoclonal antibody drugs and biosimilars comprising rituximab injection which is in Phase III clinical trials for the treatment of CD20-positive diffuse large B-cell/follicular non-Hodgkin lymphoma and chronic lymphocytic leukemia; adalimumab injection which is in Phase III clinical trials for the treatment of various autoimmune diseases; denosumab injection which is in Phase III clinical trials for the treatment of patients with bone metastases; injectable trastuzumab which is in Phase III clinical trials for the treatment of HER2-positive metastatic/early-stage breast cancer and metastatic gastric cancer; and recombinant Exendin-4-FC fusion protein injection which is in Phase I/II clinical trials for the treatment of type 2 diabetes. Further, it is involved in the research and development of poultry farming; plasma collection; engineering technology research and experimental development; and inspection and testing services. The company was founded in 1992 and is headquartered in Xinxiang, China.